These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 3827603)

  • 41. Comparative absorption and pharmacokinetic studies on proxyphylline in ordinary and slow release tablets.
    Graffner C; Johnsson G; Sjögren J
    Acta Pharm Suec; 1974 May; 11(2):125-32. PubMed ID: 4417816
    [No Abstract]   [Full Text] [Related]  

  • 42. [A case of sustained-release theophylline (Theodur)-induced asthma].
    Suenaga N; Nakamura H; Kurusu M; Nishioka Y; Kitada O; Sugita M
    Nihon Kyobu Shikkan Gakkai Zasshi; 1991 Nov; 29(11):1495-8. PubMed ID: 1770692
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.
    Wangemann M; Retzow A; Vens-Cappell B
    Int J Clin Pharmacol Ther; 1999 Feb; 37(2):100-8. PubMed ID: 10082174
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Absolute bioavailability of theophylline (Euphylline)].
    Somogyi A; Gugler R
    Fortschr Med; 1980 Nov; 98(43):1707-10. PubMed ID: 7450653
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative absorption of theophylline following multiple doses of a sustained-release formulation and an elixir in humans.
    Harrison LI; French IW; Mildon CA
    Clin Ther; 1982; 4(6):489-96. PubMed ID: 7093982
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bioavailability and absorption kinetics of slow-release theophylline.
    Boner A; De Stefano G; Messori A; Plebani M; Vallone G; Martini N
    Drug Intell Clin Pharm; 1987 Feb; 21(2):221-2. PubMed ID: 3829917
    [No Abstract]   [Full Text] [Related]  

  • 47. Erratic absorption of a slow-release theophylline sprinkle product.
    Pedersen S; Møller-Petersen J
    Pediatrics; 1984 Oct; 74(4):534-8. PubMed ID: 6483520
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Circadian variation in the absorption of three sustained release theophylline products in asthmatic children and the effect of food on absorption of Somophyllin-CRT.
    Birkett DJ; Coulthard KP; Lines D; Grgurinovich N
    Br J Clin Pract Suppl; 1984; 35():17-23. PubMed ID: 6433954
    [No Abstract]   [Full Text] [Related]  

  • 49. Evaluation of bioavailability by different methods.
    Ritschel WA; Hussain SA; Schneider B; Betzien G; Kaufmann B
    Methods Find Exp Clin Pharmacol; 1985 Aug; 7(8):439-49. PubMed ID: 4079595
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative bioavailability of a new sustained-release theophylline tablet.
    Takagi K; Watanabe T; Satake T; Hasegawa T; Ogura Y; Imaeda N; Mizukami Y
    Arerugi; 1987 Nov; 36(11):1006-11. PubMed ID: 3442492
    [No Abstract]   [Full Text] [Related]  

  • 51. [Biological availability of two theophylline preparations (author's transl)].
    Kaik G
    Prax Klin Pneumol; 1982 Jun; 36(6):294-6. PubMed ID: 7111181
    [No Abstract]   [Full Text] [Related]  

  • 52. New method for bioavailability assessment of slow-release preparations of theophylline.
    Kasuya Y; Ohno T; Kubota N; Takahashi H; Hirayama H
    J Pharmacokinet Biopharm; 1985 Dec; 13(6):571-87. PubMed ID: 3834072
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Forty-eight-hour absorption pharmacokinetic profiles of two sustained-release theophylline preparations.
    Green LD; Saccar CL; Helsel CL; Niehls ME; McGeady SJ; Mansmann HC
    J Asthma; 1984; 21(1):35-9. PubMed ID: 6368520
    [No Abstract]   [Full Text] [Related]  

  • 54. [Comparison between in vitro dissolution and in vivo absorption of a new form of delayed-action theophylline].
    Brazier JL; Comet F; Bannier A; Gillet A; Georges D
    Ann Pharm Fr; 1985; 43(1):55-60. PubMed ID: 4062182
    [No Abstract]   [Full Text] [Related]  

  • 55. Pharmacokinetic comparison of a once-daily and twice-daily theophylline delivery system.
    González MA; Kisicki J; Straughn AB
    Clin Ther; 1994; 16(4):686-92. PubMed ID: 7982257
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of a 12-hour sustained-release preparation in maintaining therapeutic serum theophylline levels in asthmatic children.
    Kelly HW; Murphy S
    Pediatrics; 1980 Jul; 66(1):97-102. PubMed ID: 7402798
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system.
    González MA; Straughan AB
    Clin Ther; 1994; 16(5):804-14. PubMed ID: 7859239
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Relative deconvolution. An explicit method for bioavailability comparison not requiring intravenous administration.
    Veng-Pedersen P; Miller R
    Int J Clin Pharmacol Ther Toxicol; 1987 Jan; 25(1):10-4. PubMed ID: 3557723
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Euphylong. A new sustained-release theophylline pellet formulation for once-daily evening administration.
    Arzneimittelforschung; 1988 Aug; 38(8A):1199-256. PubMed ID: 3190807
    [No Abstract]   [Full Text] [Related]  

  • 60. [Influence of food on the bioavailability of theophylline in a delayed-release dosage form (Dilatrane AP)].
    Flouvat B; Delhotal-Landes B; Boutin-Pannetier MS
    Therapie; 1986; 41(2):144-5. PubMed ID: 3726788
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.